Investors cheer positive Erbitux trial

The markets are dancing with glee over Erbitux, the ImClone/Bristol-Myers cancer drug. ImClone and Bristol-Myers share prices both surged on news that the drug improved the survival rates of non-small cell lung cancer patients in a late-stage trial.

Shares in ImClone's European partner Merck KGaA also rose on the news, as analysts boosted predictions for European sales to $1.4 billion from $1.1 billion. The drug is already approved for sale in the U.S. and Europe for treatment of colon cancer, and head and neck cancer.

This new lung-cancer trial added Erbitux to a common European chemo regimen that includes vinorelbine and cisplatin. Two months ago, a similar-but-separate trial that combined Erbitux with taxane and carboplatin--two drugs commonly used in the U.S.--failed.

- check out ImClone's release
- see this report from MarketPlace

Related Articles:
ImClone names new CEO. Report
ImClone shares dive after Erbitux fails a Phase III. Report
Erbitux data underscores leaked disappointment. Report
ImClone buoyed by new Erbitux data. Report
ImClone touts survival rate in Erbitux cancer trial. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.